PA
CARM

Parallel Advisors’s Carisma Therapeutics CARM Stock Holding History

Parallel Advisors’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-38
Closed -$1K – 3100
2021
Q3 		$1K Sell
38
-27
-42% -$1.3K ﹤0.01% 2817
2021
Q2 		$6K Sell
65
-60
-48% -$3.83K ﹤0.01% 2210
2021
Q1 		$7K Sell
125
-90
-42% -$4.25K ﹤0.01% 2052
2020
Q4 		$6K Sell
215
-21
-9% -$533 ﹤0.01% 1961
2020
Q3 		$7K Buy
236
+86
+57% +$1.72K ﹤0.01% 1877
2020
Q2 		$2K Hold
150
– – ﹤0.01% 2168
2020
Q1 		$1K Buy
150
+25
+20% +$410 ﹤0.01% 2240
2019
Q4 		$3K Buy
+125
New +$2.87K ﹤0.01% 2089

Other funds holding CARM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Parallel Advisors's CARM Position: Q4 2021 in Review

Parallel Advisors sold out of Carisma Therapeutics (CARM) in Q4 2021, closing a stake of 38 shares — an estimated $1K sold.

Parallel Advisors first reported a position in CARM in Q4 2019 and held it in 8 quarters. The position peaked at $7K in Q1 2021. 93 funds tracked by Wall St. Rank hold CARM as of Q4 2021.

  • Parallel Advisors reported no remaining Carisma Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Parallel Advisors sold 38 Carisma Therapeutics shares in Q4 2021, an estimated $1K.
  • Parallel Advisors first reported a position in Carisma Therapeutics in Q4 2019 and held it in 8 quarters.
  • Parallel Advisors's Carisma Therapeutics position peaked at $7K in Q1 2021.
  • 93 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2021.

Based on Parallel Advisors's 13F filing for Q4 2021, filed 20 Jan 2022.